- Ticker
- ABCL
- Price
- 7.31
- Stock movement down
- -0.31 (-4.07%)
- Company name
- Abcellera Biologics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Marktkapitalisierung
- 2.09B
- Ent-Wert
- 2.02B
- Preis/Umsatz
- 3.47
- Preis/Buch
- 1.67
- Div-Ertrag
- -
- Div Wachstum
- -
- Wachstumsjahre
- -
- FCF-Ausschüttung
- -
- Nachlaufendes KGV
- 8.42
- Forward P/E
- -
- PEG
- -
- EPS-Wachstum
- -
- 1 Jahr Rückkehr
- -17.12%
- 3-Jahres-Rendite
- -
- 5-Jahres-Rendite
- -
- 10-Jahres-Rendite
- -
Zuletzt aktualisiert: 2023-03-22
AbCellera is pledging to discover promising antibodies for its clients and bring them to the clinic faster than anybody else. Read more about ABCL and the challenges it faces.
24. März 2023
iO Charts is a Seeking Alpha partner
Today, we take a deeper look at AbCellera Biologics whose Covid revenue stream is fading fast as the pandemic ends. Click here to see our take on ABCL stock.
23. März 2023
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABCL keine Dividenden ausschüttet
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
22. März 2023
iO Charts is a Seeking Alpha partner
The following slide deck was published by AbCellera Biologics Inc.
22. Februar 2023
iO Charts is a Seeking Alpha partner
BEWERTUNG
Bewertungskennzahlen
Loading...
Daten zu den Bewertungsverhältnissen
| Nachlaufendes KGV | 8.42 |
| Preis zu OCF | 9.10 |
| Preis zu FCF | 13.07 |
| Preis zu EBITDA | 5.54 |
| EV zu EBITDA | 5.35 |
Bewertung (Umsatz/Buchwert)
Loading...
Bewertungsdaten (Umsatz/Buchwert)
| Preis zu Umsatz | 3.47 |
| Preis zum Buchen | 1.67 |
| EV zu Verkäufen | 3.35 |
AbCellera Biologics Inc. (NASDAQ:NASDAQ:ABCL) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and Compliance OfficerCarl Hansen -...
22. Februar 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
21. Februar 2023
iO Charts is a Seeking Alpha partner
FINANZEN
Pro Aktie
Loading...
Angaben pro Aktie
| Aktuelle Anzahl der Aktien | 286.10M |
| EPS (TTM) | 0.79 |
| FCF pro Aktie (TTM) | 0.51 |
Gewinn- und Verlustrechnung
Loading...
Daten der Gewinn- und Verlustrechnung
| Umsatz (TTM) | 603.21M |
| Bruttogewinn (TTM) | 516.44M |
| Betriebsergebnis (TTM) | 335.84M |
| Reingewinn (TTM) | 248.36M |
| EPS (TTM) | 0.79 |
| EPS (1 Jahr vorwärts) | -0.45 |
Margen
Loading...
Daten zu den Margen
| Bruttomarge (TTM) | 85.61% |
| Operative Marge (TTM) | 55.68% |
| Gewinnspanne (TTM) | 41.17% |
Bilanz
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Bilanzdaten
| Bargeld | 371.97M |
| Nettoforderungen | 105.96M |
| Umlaufvermögen insgesamt | 1.05B |
| Goodwill | 47.81M |
| Immaterielle Vermögenswerte | 142.55M |
| Sachanlagen und Ausrüstung | 0.00 |
| Gesamtvermögen | 1.55B |
| Verbindlichkeiten aus Lieferungen und Leistungen | 9.32M |
| Kurz-/kurzfristige langfristige Schulden | 76.11M |
| Kurzfristige Verbindlichkeiten insgesamt | 106.05M |
| Verbindlichkeiten insgesamt | 302.24M |
| Aktionärseigenkapital | 1.25B |
| Netto-Sachanlagen | 1.06B |
Cashflow
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Cashflow-Daten
| Operativer Cashflow (TTM) | 229.74M |
| Investitionsausgaben (TTM) | 69.76M |
| Freier Cashflow (TTM) | 159.98M |
| Ausgeschüttete Dividenden (TTM) | 0.00 |
Finanzielle Erträge
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Daten zu Finanzerträgen
| Eigenkapitalrendite | 19.87% |
| Kapitalrendite | 16.00% |
| Rentabilität des investierten Kapitals | 19.79% |
| Cash Return on Invested Capital | 12.75% |
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
20. Februar 2023
iO Charts is a Seeking Alpha partner
In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. See why I'm fervently bullish on ABCL stock.
5. Januar 2023
iO Charts is a Seeking Alpha partner
BESTANDSINFORMATIONEN
Aktienchart
Loading...
Daten zum Aktienkurs
| Öffnen Sie | 7.69 |
| Tageshöchststand | 7.70 |
| Tägliches Tief | 7.30 |
| Tägliches Volumen | 1.18M |
| Allzeithoch | 53.20 |
| 1-Jahres-Analystenschätzung | 29.20 |
| Beta | -0.24 |
| EPS (TTM) | 0.79 |
| Dividende je Aktie | - |
| Ex-Div-Datum | - |
| Nächstes Ergebnisdatum | 8 May 2023 |
Nachteiliges Potenzial
Loading...
Nachteilige potenzielle Daten
| ABCL | S&P500 | |
| Aktueller Preisrückgang vom Allzeithoch | -86.26% | -17.92% |
| Höchster Preisrückgang | -89.25% | -56.47% |
| Datum des höchsten Rückgangs | 11 May 2022 | 9 Mar 2009 |
| Durchschnittlicher Rückgang vom Höchststand | -67.13% | -11.51% |
| Durchschnittliche Zeit bis zum neuen Höchststand | 114 days | 13 days |
| Maximale Zeit bis zum neuen Höchststand | 539 days | 1805 days |
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
15. Dezember 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
1. Dezember 2022
iO Charts is a Seeking Alpha partner
UNTERNEHMENSDATEN
Marketcap
2.09B
Kategorie Marktkapitalisierung
Mid-cap
Beschreibung
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Mitarbeiter
475
Website
Investor Relations
-
SEC-Anmeldungen
CEO
Land
USA
Stadt
Art des Bestands
-
CCC-Status
-
Häufigkeit der Ausschüttung
-
VERANSTALTUNGEN UND PRÄSENTATIONEN
VeranstaltungenPräsentationen
Loading...
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
30. November 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
16. November 2022
iO Charts is a Seeking Alpha partner
DAS GESCHÄFT VERSTEHEN
Loading...
AbCellera Biologics has multiple high-value opportunities that should become clear in the next few years. Find out why I'm confident in the long-term return potential of ABCL.
9. November 2022
iO Charts is a Seeking Alpha partner
AbCellera Biologics Inc (NASDAQ:NASDAQ:ABCL) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and Compliance OfficerCarl Hansen -...
9. November 2022
iO Charts is a Seeking Alpha partner
UNTERNEHMENSNACHRICHTEN
Alle NachrichtenPresseveröffentlichungen
If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you’re obviously going to need to conduct heavy research on the sto...
22. März 2023
VANCOUVER, British Columbia & LONDON, March 22, 2023--AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
22. März 2023
VANCOUVER, British Columbia, March 14, 2023--AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
14. März 2023
Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable...
12. März 2023
VANCOUVER, British Columbia, February 23, 2023--AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
23. Februar 2023
Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL)Q4 2022 Earnings CallFeb 21, 2023, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: ...
22. Februar 2023
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the ...
21. Februar 2023
VANCOUVER, British Columbia, February 21, 2023--AbCellera Reports Full Year 2022 Business Results
21. Februar 2023
You don’t have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edg...
2. Februar 2023
VANCOUVER, British Columbia, February 01, 2023--AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
1. Februar 2023
Nächste Seite
The following slide deck was published by AbCellera Biologics Inc.
8. November 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
8. November 2022
iO Charts is a Seeking Alpha partner